{"id":18974,"date":"2021-02-09T11:37:28","date_gmt":"2021-02-09T10:37:28","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=18974"},"modified":"2021-02-09T11:44:13","modified_gmt":"2021-02-09T10:44:13","slug":"interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/","title":{"rendered":"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M"},"content":{"rendered":"\n

InteRNA Technologies<\/a> announced today the closing of an extended Series B financing round amounting to EUR 18.5M in total. This Series B round was led by AurorA Science<\/a>, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round. The funding will enable the clinical evaluation of the Company\u2019s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors. Furthermore, the proceeds will be used to develop and advance additional proprietary preclinical drug candidates adressing a variety of cancer indications thereby expanding the Company\u2019s pipeline. As part of the Series B financing, Gabriele Campi, PhD, of AurorA Science will join the Board of Directors.<\/p>\n\n\n\n

\u201cThis successful extension of the Series B financing round validates the unique potential that microRNAs offer as a therapeutic modality for hard-to-treat cancers,\u201d said Dr. Roel Schaapveld, CEO of InteRNA Technologies. \u201cWe thank AurorA Science, Waterman Ventures and our other long-term investors for their support in bringing our microRNA technology into the clinic and look forward to evaluate INT-1B3\u2019s unique mode of action, targeting not only the tumor cells themselves but also the disease-promoting tumor microenvironment.\u201d<\/p>\n\n\n\n

\u201cWith this participation in InteRNA Technologies, AurorA Science continues its strong commitment into front-edge science,\u201d commented Guido Guidi, Chairman at AurorA Science. \u201cWe believe InteRNA has developed a promising innovative technology in this area and look forward to supporting the team on their path forward.\u201d microRNAs are naturally occurring, non-coding strands of RNA that trigger the RNA interference pathway and regulate gene expression by controlling the efficiency of messenger RNA (mRNA) translation into functional proteins. InteRNA designs breakthrough therapies tackling cancer by using the inherent characteristic of microRNAs to simultaneously inhibit multiple mRNA targets in a coordinated fashion, e.g. by blocking activated cancer signaling pathways and preventing activation of alternative disease-promoting pathways. <\/p>\n\n\n\n

Source: InteRNA (Press release<\/a>)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

InteRNA Technologies announced today the closing of an extended Series B financing round amounting to EUR 18.5M in total. This Series B round was led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round. The funding will […]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-18974","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"\nInteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M - hollandbio\" \/>\n<meta property=\"og:description\" content=\"InteRNA Technologies announced today the closing of an extended Series B financing round amounting to EUR 18.5M in total. This Series B round was led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round. The funding will […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-09T10:37:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-09T10:44:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"HollandBIO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"HollandBIO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/\"},\"author\":{\"name\":\"HollandBIO\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\"},\"headline\":\"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M\",\"datePublished\":\"2021-02-09T10:37:28+00:00\",\"dateModified\":\"2021-02-09T10:44:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/\"},\"wordCount\":326,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/\",\"name\":\"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2021-02-09T10:37:28+00:00\",\"dateModified\":\"2021-02-09T10:44:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\",\"name\":\"HollandBIO\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/","og_locale":"en_US","og_type":"article","og_title":"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M - hollandbio","og_description":"InteRNA Technologies announced today the closing of an extended Series B financing round amounting to EUR 18.5M in total. This Series B round was led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round. The funding will […]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/","og_site_name":"hollandbio","article_published_time":"2021-02-09T10:37:28+00:00","article_modified_time":"2021-02-09T10:44:13+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"HollandBIO","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"HollandBIO","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/"},"author":{"name":"HollandBIO","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea"},"headline":"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M","datePublished":"2021-02-09T10:37:28+00:00","dateModified":"2021-02-09T10:44:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/"},"wordCount":326,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/","name":"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2021-02-09T10:37:28+00:00","dateModified":"2021-02-09T10:44:13+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/interna-technologies-extends-series-b-financing-round-totaling-eur-18-5m\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea","name":"HollandBIO"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/18974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=18974"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/18974\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=18974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=18974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=18974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}